Design of Nanozymes for Inflammatory Bowel Disease Therapy

Cheng Chaoqun,Zhao Sheng,Cheng Yuan,Liu Yufeng,Wei Hui

DOI: https://doi.org/10.1007/s11427-020-1937-6

2021-01-01

Science China Life Sciences

Abstract:Nanozymes,the functional nanomaterials with enzyme-like activities,have been widely explored for both in vitro and in vivo applications(Wei and Wang,2013;Wu et al.,2019;Huang et al.,2019;Liang and Yan,2019).Particularly,by modulating the levels of reactive oxygen species(ROS)in vivo,numerous therapeutic nanozymes have been developed to treat diseases,ranging from cancer to neurodegenerative diseases(Fan et al.,2018;Kwon et al.,2018).Despite these successes,applying the therapeutic nanozymes to clinical translation is still full of diffculties and challenges.We per-formed an analysis on the in vivo applications of nanozymes to identify these challenges(Figure S1 in Supporting In-formation).It revealed that first,both pristine and functio-nalized nanozymes are used for in vivo applications,and functionalized nanozymes are dominant(60.08％).Among the functionalized nanozymes,only 11.02％ have the tar-getting moieties.It indicates that 88.98％ of nanozymes are not able to specifically target disease sites,which would in turn lead to severe adverse effects.Second,only 3.8％ of the in vivo nanozymes can be cleared or degraded and then eliminated.Therefore,the clearable or degradable nano-zymes are needed to minimize their long-term toxicity con-cerns.